Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Dermatol ; 36(12): 628-31, 2009 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19958445

RESUMO

Palmoplantar hyperhidrosis (PPH) is a disorder characterized by excessive sweating of the palmar surfaces of the hands and feet due to emotional sweating. There have been reports based on family histories, and the involvement of genetic factors has been suggested. Among 410 PPH patients who visited our hospital from August 2006 to October 2008, onset age and family history were investigated in order to prepare pedigree charts, and family histories were confirmed in 147 patients (36%). Between the family history and negative family history (sporadic) groups, no significant differences were seen in onset age, sex or sweat volume. With regard to the patterns of incidence within families, parent-child was the most common at 58%, followed by sibling cases at 18%. The incidence of PPH in three generations was 13%. Pedigree charts prepared based on data obtained by patient interviews suggested autosomal dominant inheritance.


Assuntos
Hiperidrose/genética , Adulto , Feminino , Genes Dominantes , Humanos , Hiperidrose/fisiopatologia , Japão , Masculino , Linhagem , Suor/metabolismo
2.
J Cutan Pathol ; 36(5): 517-21, 2009 May.
Artigo em Inglês | MEDLINE | ID: mdl-19476518

RESUMO

BACKGROUND: With regards to dyshidrosis in Parkinson's disease (PD), there is no established and consistent view on the occurrence sites, frequency and etiology, although there have been several reports on hypohidrosis of the limbs and sudoresis on the face/cervical region. METHODS: Hydrosis in the forearms of PD patients and healthy individuals were compared by quantitative sudomotor axon reflex test (QSART). The expression of various neuropeptides and alpha-synuclein was examined with immunohistochemical staining. RESULTS: There was a significant reduction in QSART of PD patients but not of healthy controls. Reduced expression of vasoactive intestinal polypeptide (VIP) was also detected in the sweat glands of PD patients. CONCLUSION: Reduction in QSART and VIP expression in the sweat glands might be involved in the dyshidrosis of PD patients.


Assuntos
Doença de Parkinson/complicações , Reflexo/fisiologia , Pele/fisiopatologia , Doenças das Glândulas Sudoríparas/fisiopatologia , Peptídeo Intestinal Vasoativo/biossíntese , Idoso , Axônios/fisiologia , Estimulação Elétrica , Feminino , Humanos , Imuno-Histoquímica , Masculino , Doença de Parkinson/metabolismo , Doença de Parkinson/fisiopatologia , Pele/metabolismo , Doenças das Glândulas Sudoríparas/etiologia , Doenças das Glândulas Sudoríparas/metabolismo , Glândulas Sudoríparas/inervação , Glândulas Sudoríparas/metabolismo , alfa-Sinucleína/biossíntese
3.
J Dermatol ; 35(6): 325-9, 2008 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-18578708

RESUMO

Botulinum toxin A is widely used in Europe and the USA for the treatment of localized hyperhidrosis, and its efficacy has been recognized. In this study, botulinum toxin A (Botox) was locally injected at 30 sites (2 U/injection) on the right palm in 27 patients with palmar hyperhidrosis (14 severe patients, 13 mild patients), and the results confirmed the efficacy of injection. The amount of sweat was then quantified for the left and right hands every month after local injection. The quantity of sweat on the treated hand was approximately one-fifth that on the untreated hand. In addition, the quantity of sweat on the untreated hand decreased slightly. Over time, the quantity of sweat on the treated hand increased slightly, but the quantity of sweat on the treated hand at 6 months after injection was less than half that before injection, and there were significant differences before and after injection. In the present study, severe sweating was defined as 1 mg/cm2/min or more and mild sweating as less than 1 mg/cm2/min, and the therapeutic effects of botulinum toxin A were analyzed in relation to severity. When compared to the mild cases, the quantity of sweat remained higher in the severe cases after botulinum toxin A therapy. Therefore, to achieve satisfactory effects in severe cases, it would be necessary to increase the number of injection sites, as well as injection dose.


Assuntos
Toxinas Botulínicas Tipo A/uso terapêutico , Hiperidrose/tratamento farmacológico , Neurotoxinas/uso terapêutico , Suor/metabolismo , Adulto , Feminino , Mãos , Humanos , Injeções Subcutâneas , Iodo , Masculino , Índice de Gravidade de Doença , Resultado do Tratamento
4.
Photodermatol Photoimmunol Photomed ; 24(3): 142-6, 2008 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-18477133

RESUMO

BACKGROUND/PURPOSE: 5-aminolaevulinic acid-based photodynamic therapy (ALA-PDT) is widely performed in the clinical setting for superficial skin cancers, giving favorable results, but residual tumor and recurrence occur occasionally. Thioredoxin is a common antioxidant that suppresses apoptosis and facilitates cell growth. We investigated the expression of thioredoxin following ALA-PDT in human skin squamous cell carcinoma cell line, HSC-5. METHODS: ALA-PDT was performed in HSC-5 cells using low-dose (5 J/cm(2), 100 mW/cm(2)) or high-dose (30 J/cm(2), 100 mW/cm(2)) irradiation, and the expression of thioredoxin was measured by Western blotting. An MTT assay was used to assess cell growth following a low dose of multiple irradiations. Cell death was examined by Western blotting for caspase-3 and PARP. Immunofluorescence double staining using annexin V and propidium iodine was also performed. RESULTS: Expression of thioredoxin was only observed following low-dose exposure ALA-PDT. Multiple low-dose exposure ALA-PDT significantly proliferated cell growth. With high-dose exposure ALA-PDT, caspase-3 and PARP expression were seen, and cell death due to apoptosis and/or necrosis was observed, but thioredoxin was barely detected. CONCLUSION: Low-dose exposure ALA-PDT increased the expression of thioredoxin and facilitated the growth of HSC-5 cells.


Assuntos
Ácido Aminolevulínico/farmacologia , Carcinoma de Células Escamosas/metabolismo , Morte Celular/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Fotoquimioterapia , Fármacos Fotossensibilizantes/farmacologia , Tiorredoxinas/metabolismo , Ácido Aminolevulínico/efeitos adversos , Análise de Variância , Western Blotting , Carcinoma de Células Escamosas/tratamento farmacológico , Carcinoma de Células Escamosas/patologia , Caspase 3/metabolismo , Morte Celular/fisiologia , Linhagem Celular Tumoral , Colágeno Tipo XI/metabolismo , Humanos , Lasers de Corante , Microscopia de Fluorescência , Recidiva Local de Neoplasia/induzido quimicamente , Fotoquimioterapia/efeitos adversos , Fotoquimioterapia/métodos , Fármacos Fotossensibilizantes/efeitos adversos , Doses de Radiação , Regulação para Cima/efeitos dos fármacos
5.
Artigo em Inglês | MEDLINE | ID: mdl-17523931

RESUMO

BACKGROUND: Sezary syndrome and mycosis fungoides are forms of cutaneous T-cell lymphoma, and in the early stage of these diseases psoralen plus ultraviolet A (PUVA) is one of the treatments of choice. Photodynamic therapy using 5-aminolevulinic acid (ALA-PDT) is an effective, non-invasive, and safe treatment for most superficial skin cancers. In order to obtain greater efficacy of PUVA, we investigated the synergistic anti-tumor effects of ALA-PDT and PUVA using 8-methoxypsoralen (8-MOP) and a UVA lamp. METHODS: The in vitro effects of PUVA and ALA-PDT and their combination in HUT-78 cell line from human SS were determined by MTT assay. RESULTS: In our results, cell proliferation compared with controls was inhibited to 53.2% with UVA alone, 52.3% with 1 microM 8-MOP, 43.8% with 100 microM ALA, and 19.2% with combined 8-MOP and ALA. CONCLUSION: Combined use of ALA and PUVA using 8-MOP and UVA lamps, which are widespread in Japan, had a strong anti-tumor effect in vitro. Combined treatment with ALA-PDT and PUVA using a UVA lamp appears to have a strong treatment effect.


Assuntos
Ácido Aminolevulínico/administração & dosagem , Metoxaleno/administração & dosagem , Terapia PUVA , Fármacos Fotossensibilizantes/administração & dosagem , Neoplasias Cutâneas/tratamento farmacológico , Linhagem Celular Tumoral/efeitos dos fármacos , Linhagem Celular Tumoral/efeitos da radiação , Proliferação de Células/efeitos dos fármacos , Proliferação de Células/efeitos da radiação , Sinergismo Farmacológico , Humanos , Micose Fungoide/tratamento farmacológico , Micose Fungoide/patologia , Síndrome de Sézary/tratamento farmacológico , Síndrome de Sézary/patologia , Raios Ultravioleta
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...